Bio-Rad Laboratories, Inc.
BIO
Rangering i aksjer
#2165
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules,... Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
Aksjekurs
$355.52
Markedsverdi
$9.51B
Endring (1 dag)
0.98%
Endring (1 år)
10.44%
Land
US
Handel Bio-Rad Laboratories, Inc. (BIO)
Kategori
Healthcare
P/E-forhold for Bio-Rad Laboratories, Inc. (BIO)
P/E-forhold per October 2026 TTM: 43.51
Ifølge Bio-Rad Laboratories, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 43.51. Ved slutten av 2023 hadde selskapet en P/E på -14.80.
P/E-forholdshistorikk for Bio-Rad Laboratories, Inc. fra 2000 til 2026
P/E-forhold ved slutten av hvert år
| År | P/E-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 43.51 | -964.99% |
| 2024 | -5.03 | -66.04% |
| 2023 | -14.80 | 328.61% |
| 2022 | -3.45 | -165.17% |
| 2021 | 5.30 | 16.45% |
| 2020 | 4.55 | -27.54% |
| 2019 | 6.28 | -67.28% |
| 2018 | 19.19 | -68.89% |
| 2017 | 61.69 | -67.67% |
| 2016 | 190.80 | 433.20% |
| 2015 | 35.78 | -8.68% |
| 2014 | 39.18 | -13.74% |
| 2013 | 45.42 | 158.67% |
| 2012 | 17.56 | 16.26% |
| 2011 | 15.11 | -2.48% |
| 2010 | 15.49 | -15.26% |
| 2009 | 18.28 | -19.87% |
| 2008 | 22.81 | -23.37% |
| 2007 | 29.77 | 41.23% |
| 2006 | 21.08 | 0.79% |
| 2005 | 20.91 | -3.29% |
| 2004 | 21.63 | 12.38% |
| 2003 | 19.24 | 34.25% |
| 2002 | 14.33 | -18.83% |
| 2001 | 17.66 | 41.42% |
| 2000 | 12.49 | 0.00% |
P/E-forhold for lignende selskaper eller konkurrenter
| Selskap | P/E-forhold | Forskjell i P/E-forhold | Land |
|---|---|---|---|
| 33.11 | -23.90% |
US
|
|
| 21.39 | -50.84% |
IE
|
|
| 28.94 | -33.47% |
US
|
|
| 17.34 | -60.15% |
US
|
|
| - | - |
DE
|
Hvordan lese en P/E-ratio?
Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.
Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.
Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.